Astex Pharmaceuticals
Pharmaceutical company / From Wikipedia, the free encyclopedia
Astex Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell,[1][2] Chris Abell & Harren Jhoti,[3] and is located in Cambridge, England.[4][5][6][7][8]
Quick Facts Company type, Traded as ...
Company type | Subsidiary |
---|---|
Nasdaq: ASTX | |
Industry | Pharmaceuticals |
Founded | 1999; 25 years ago (1999) |
Headquarters | European Corporate and Research headquarters in Cambridge, UK (Astex Therapeutics Limited) US Corporate and Clinical Development headquarters in Pleasanton, California, USA (Astex Pharmaceuticals Inc.) |
Key people | Harren Jhoti (president and CEO) David Rees (Chief Scientific Officer, Astex Therapeutics Limited) Martin Buckland (President and Chief Corporate Officer, Astex Pharmaceuticals Inc.) Harold N. Keer (Chief Medical Officer, Astex Pharmaceuticals Inc.) |
Products | Therapeutics for oncology and CNS disorders |
Parent | Otsuka Pharmaceutical |
Website | astx |
Close
Astex is part of the Otsuka group of companies and is a wholly-owned subsidiary of Otsuka Pharmaceutical Co. Ltd, headquartered in Tokyo, Japan.[9]